Loco-Regional Treatment for Intact Primary Tumor in Patient with De Novo Metastatic Breast Cancer; Comments and Concerns of ECOG-ACRIN 2108 Trial

摘要

Khan et al. ( ) presented the results of the multicenter, phase 3, ECOG ACRIN 2108 study at the plenary session of ASCO 2020 virtual meeting earlier than expected. ECOG-ACRIN 2108 (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network - ) trial recruited 390 women with de novo metastatic breast cancer (MBC) from February 2011 through July 2015 to determine whether the addition of locoregional treatment improved overall survival (OS). While 134 of these cases were excluded from the study for different reasons, 256 eligible patients were assigned to systemic therapy based on patient and tumor characteristics. Those who did not progress during 4 to 8 months of treatment were then assigned to continue systemic therapy alone (ST - n=131) or ST plus locoregional treatment with surgery +/- radiation (LRT - n=125).